ASH 2021 | Developments in the FL treatment landscape
Ryan Lynch
• 13 Dec 2021
Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, provides an overview of promising therapies for follicular lymphoma (FL). Whilst chemoimmunotherapy remains the standard of care for frontline treatment-naïve patients, patients who have relapsed/refractory FL can receive a wide range of therapies including lenalidomide, rituximab, PI3K inhibitors, EZH2 inhibitors, and chimeric antigen receptor (CAR) T-cell therapy. Dr Lynch additionally highlights the development of bispecific antibodies and the importance of choosing the right therapy based on patient characteristics and their wishes. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
